Bin Li
Research Subjects
Bin Li has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Bo Hang
Biological Systems and Engineering Division, Lawrence Berkeley National Laboratory, Berkeley, USA
1 shared publication - Carlos O. RodriguezJr
Department of Surgical and Radiological Sciences, University of California, Davis, CA, USA
1 shared publication Chengfei Jiang
1 shared publication- Chong-Xian Pan
Department of Medicine Harvard Medical School Boston Massachusetts USA
1 shared publication Dexi Jin
1 shared publicationFeng Tao
1 shared publication
Latest Publications
- Open Access
- 1 November 2020
- Published by Elsevier in EBioMedicine
- Vol. 61
Clinically applicable 53-Gene prognostic assay predicts chemotherapy benefit in gastric cancer: A multicenter study
- 1 November 2020
- Published by Elsevier in EBioMedicine
- Vol. 61
Open AccessClinically applicable 53-Gene prognostic assay predicts chemotherapy benefit in gastric cancer: A multicenter study
- Open Access
- 27 January 2011
- Published by Springer Nature in Molecular Cancer
- Vol. 10 (1) , 9
Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand
Objective: To determine if a human bladder cancer-specific peptide named PLZ4 can target canine bladder cancer cells. Experimental Design: The binding of PLZ4 to five established canine invasive transitional cell carcinoma (TCC) cell lines and to normal canine bladder urothelial cells was determined using the whole cell binding assay and an affinitofluorescence assay. The WST-8 assay was performed to determine whether PLZ4 affected cell viability. In vivo tumor-specific homing/targeting property and biodistribution of PLZ4 was performed in a mouse xenograft model via tail vein injection and was confirmed with ex vivo imaging. Results: PLZ4 exhibited high affinity and specific dose-dependent binding to canine bladder TCC cell lines, but not to normal canine urothelial cells. No significant changes in cell viability or proliferation were observed upon incubation with PLZ4. The in vivo and ex vivo optical imaging study showed that, when linked with the near-infrared fluorescent dye Cy5.5, PLZ4 substantially accumulated at the canine bladder cancer foci in the mouse xenograft model as compared to the control. Conclusions and Clinical Relevance: PLZ4 can specifically bind to canine bladder cancer cells. This suggests that the preclinical studies of PLZ4 as a potential diagnostic and therapeutic agent can be performed in dogs with naturally occurring bladder cancer, and that PLZ4 can possibly be developed in the management of canine bladder cancer.
- 27 January 2011
- Published by Springer Nature in Molecular Cancer
- Vol. 10 (1) , 9
Open AccessTargeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand
Objective: To determine if a human bladder cancer-specific peptide named PLZ4 can target canine bladder cancer cells. Experimental Design: The binding of PLZ4 to five established canine invasive transitional cell carcinoma (TCC) cell lines and to normal canine bladder urothelial cells was determined using the whole cell binding assay and an affinitofluorescence assay. The WST-8 assay was performed to determine whether PLZ4 affected cell viability. In vivo tumor-specific homing/targeting property and biodistribution of PLZ4 was performed in a mouse xenograft model via tail vein injection and was confirmed with ex vivo imaging. Results: PLZ4 exhibited high affinity and specific dose-dependent binding to canine bladder TCC cell lines, but not to normal canine urothelial cells. No significant changes in cell viability or proliferation were observed upon incubation with PLZ4. The in vivo and ex vivo optical imaging study showed that, when linked with the near-infrared fluorescent dye Cy5.5, PLZ4 substantially accumulated at the canine bladder cancer foci in the mouse xenograft model as compared to the control. Conclusions and Clinical Relevance: PLZ4 can specifically bind to canine bladder cancer cells. This suggests that the preclinical studies of PLZ4 as a potential diagnostic and therapeutic agent can be performed in dogs with naturally occurring bladder cancer, and that PLZ4 can possibly be developed in the management of canine bladder cancer.